Clinical Trial Update: Safety and Efficacy of CD10367 in Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of CD10367 in adults with psoriasis vulgaris; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• CD10367

Snippet

Sponsor: Galderma R&D | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19